| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies
|
Massari, Francesco
|
|
2018
|
68 |
C |
p. 80-85
|
artikel
|
| 2 |
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|
Gerratana, L.
|
|
2018
|
68 |
C |
p. 102-110
|
artikel
|
| 3 |
Assessment of the risk of antiangiogenic agents before and after surgery
|
Bailey, Christina E.
|
|
2018
|
68 |
C |
p. 38-46
|
artikel
|
| 4 |
Borderline resectable pancreatic cancer. Challenges and controversies
|
Sabater, Luis
|
|
2018
|
68 |
C |
p. 124-135
|
artikel
|
| 5 |
Burnout in oncologists is a serious issue: What can we do about it?
|
Murali, Krithika
|
|
2018
|
68 |
C |
p. 55-61
|
artikel
|
| 6 |
Cardiotoxicity associated with radiotherapy in breast cancer: A question-based review with current literatures
|
Zhu, Qian
|
|
2018
|
68 |
C |
p. 9-15
|
artikel
|
| 7 |
Clinical development of HER3-targeting monoclonal antibodies: Perils and progress
|
Jacob, Wolfgang
|
|
2018
|
68 |
C |
p. 111-123
|
artikel
|
| 8 |
Does pelvic radiation increase rectal cancer incidence? – A systematic review and meta-analysis
|
Rombouts, A.J.M.
|
|
2018
|
68 |
C |
p. 136-144
|
artikel
|
| 9 |
Editorial Board
|
|
|
2018
|
68 |
C |
p. ii
|
artikel
|
| 10 |
Emerging therapeutic modalities of PARP inhibitors in breast cancer
|
Wang, Xin
|
|
2018
|
68 |
C |
p. 62-68
|
artikel
|
| 11 |
Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned
|
Arndt, Carola A.S.
|
|
2018
|
68 |
C |
p. 94-101
|
artikel
|
| 12 |
Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets?
|
Lefranc, Florence
|
|
2018
|
68 |
C |
p. 145-154
|
artikel
|
| 13 |
Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment
|
El Rassy, Elie
|
|
2018
|
68 |
C |
p. 69-79
|
artikel
|
| 14 |
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
|
Raoul, Jean-Luc
|
|
2018
|
68 |
C |
p. 16-24
|
artikel
|
| 15 |
Targeted alpha therapy using Radium-223: From physics to biological effects
|
Marques, I.A.
|
|
2018
|
68 |
C |
p. 47-54
|
artikel
|
| 16 |
The relationship between anticipated response and subsequent experience of cancer treatment-related side effects: A meta-analysis comparing effects before and after treatment exposure
|
Fletcher, Chloe
|
|
2018
|
68 |
C |
p. 86-93
|
artikel
|
| 17 |
The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer
|
Saad, Fred
|
|
2018
|
68 |
C |
p. 25-37
|
artikel
|
| 18 |
Toward innovative combinational immunotherapy: A systems biology perspective
|
Li, Xue-Tao
|
|
2018
|
68 |
C |
p. 1-8
|
artikel
|
Tijdschrift beschrijving